Table 3 Time-to-onset analysis of bisphosphonates
Dosage form | Drug name | Case (number for analysis) | Median of time-to-onset (day) | Lower quartile of time-to-onset (day) | Upper quartile of time-to-onset (day) | Scale parameter: α | Shape parameter: β | ||
|---|---|---|---|---|---|---|---|---|---|
α | (95 % CI) | β | (95 % CI) | ||||||
Intravenous | Alendronate (I.V.) | 10 (6) | 1,342 | 691 | 1,701 | 1267.6 | (737.0 − 2125.0) | 2.15 | (0.96 − 3.83) |
Pamidronate | 223 (118) | 812 | 567 | 1,227 | 934.7 | (816.9 − 1066.3) | 1.45 | (1.26 − 1.64) | |
Zoledronate | 809 (408) | 486 | 274 | 821 | 631.5 | (586.8 − 678.9) | 1.41 | (1.30 − 1.52) | |
Oral | Alendronate (oral) | 414 (196) | 863 | 432 | 1,463 | 1095.4 | (970.2 − 1233.8) | 1.23 | (1.09 − 1.37) |
Etidronate | 16 (9) | 1,461 | 389 | 2,068 | 1390.3 | (766.8 − 2442.7) | 1.49 | (0.74 − 2.63) | |
Minodronate | 45 (32) | 432 | 196 | 742 | 629.5 | (408.3 − 954.8) | 0.90 | (0.69 − 1.13) | |
Risedronate | 152 (65) | 730 | 215 | 1,494 | 951.7 | (730.3 − 1228.7) | 1.02 | (0.82 − 1.24) | |